Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
8. lappuse
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. Subpart D - Records and Reports 310.303 Continuation of long - term studies , records , and reports on ...
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. Subpart D - Records and Reports 310.303 Continuation of long - term studies , records , and reports on ...
59. lappuse
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. 314 of this chapter is required for mar- keting . In the absence of an approved new drug application ...
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. 314 of this chapter is required for mar- keting . In the absence of an approved new drug application ...
206. lappuse
... contain no alcohol ( 0 percent ) . ( f ) For any OTC drug product in- tended for oral ingestion containing over 5 percent alcohol and labeled for use by adults and children 12 years of age and over , the labeling shall contain the ...
... contain no alcohol ( 0 percent ) . ( f ) For any OTC drug product in- tended for oral ingestion containing over 5 percent alcohol and labeled for use by adults and children 12 years of age and over , the labeling shall contain the ...
221. lappuse
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. from the market , if they have not al- ready been removed . Regulatory action will also be undertaken ...
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. from the market , if they have not al- ready been removed . Regulatory action will also be undertaken ...
229. lappuse
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. Subpart A- [ Reserved ] Subpart B - First Aid Antibiotic Drug Products § 333.101 Scope . ( a ) An over ...
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. Subpart A- [ Reserved ] Subpart B - First Aid Antibiotic Drug Products § 333.101 Scope . ( a ) An over ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning